CD8A and cancer: Mono- or dual TIGIT and PD-1–PD-L1 blockade aims to take advantage of the curative potential of pre-existing tumor-primed T cells in cancer treatment by promoting CD8+ T cell proliferation and function, resulting in protective memory T cells that ensure tumor rejection and avoid recurrence (182–184).